How to Neuropeptide Y?

Anti-obesity agents,Stable analogs of peptide and polypeptide therapeutics,Peptides for the activation of the immune system in humans and animals,Compositions and methods for brain delivery of analgesic peptides,Compounds for control of appetite

Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

Hiro

68results about "Neuropeptide Y" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Anti-obesity agents

InactiveUS20050176643A1Polypeptide with localisation/targeting motifPeptide/protein ingredientsBlood componentPYY Peptide

The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.

View all

Owner:CONJUCHEM

Stable analogs of peptide and polypeptide therapeutics

InactiveUS7259234B2Prolong half-life in vivoLong durationNervous disorderPeptide/protein ingredientsProteolysisChemistry

The present invention relates to compositions of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof.

Stable analogs of peptide and polypeptide therapeutics

View all

Owner:BACH BIOSCI LLC

Peptides for the activation of the immune system in humans and animals

InactiveUS6440690B1Peptide/protein ingredientsNeuropeptide YHost immunityAbnormal macrophage

The present invention is directed to compositions and methods for the treatment of diseases comprising the administration of compositions comprising one or more peptide(s) having a stimulatory effect on the afflicted host's immune system. Specifically, the invention relates to methods comprising the use of cationic amphipathic peptides having an alpha-helical structure and effecting activation of macrophages when administered in a therapeutically sufficient amount. The methods of the present invention are useful for the treatment of, for example, infectious diseases or cancer.

Peptides for the activation of the immune system in humans and animals

View all

Owner:MOR AMRAM

Compositions and methods for brain delivery of analgesic peptides

ActiveUS20130034572A1Lack of effectHigh selectivityNervous disorderAntipyreticNon invasivePharmacology

The present invention relates to non-invasive brain delivery technology for centrally-acting analgesic peptides. Specifically, the invention is directed to compounds comprising an antibody or fragment thereof capable of transmigrating across the blood brain barrier (BBB) and an analgesic peptide. Compositions and methods of using the compounds or compositions are also provided.

Compositions and methods for brain delivery of analgesic peptides

View all

Owner:NAT RES COUNCIL OF CANADA

Compounds for control of appetite

InactiveUS20070197445A1Peptide/protein ingredientsMetabolism disorderDiseaseMammal

This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and peptide fragments of PP, e.g. PP(32-36), and analogs thereof, to pharmaceutical compositions containing such Y4 receptor agonists, and to methods for treatment of mammals using the same. The NPY Y4 receptor agonists may be administered to mammals either alone or in combination with NPY Y2 receptor agonists including peptide YY (PYY) (3-36), analogs thereof, and to peptide fragments of PYY(3-36), e.g. PYY(22-36) and PYY(25-36), and analogs thereof, such as to control food intake in mammals, blood pressure, cardiovascular response, libido, circadian rhythm, hyperlipidimia, chronic pancreatitis, and nonalcoholic fatty liver disease including nonalcoholic steatohepatitis.

View all

Owner:CINCINNATI UNIV OF

Novel Anti-Obesity Agents

InactiveUS20080194486A1Polypeptide with localisation/targeting motifPeptide/protein ingredientsBlood componentPYY Peptide

View all

Owner:CONJUCHEM

Therapeutic peptides

InactiveUS20160108098A1BacteriaPeptide/protein ingredientsDiabetes mellitusDisease

The present invention relates to novel analogs of PYY that have an improved therapeutic profile when compared to native human PYY. These novel PYY analogs are useful in the treatment of obesity, diabetes, and other disorders.

View all

Owner:GLAXOSMITHKLINE INTPROP DEV LTD

Process for the production of preformed conjugates of albumin and a therapeutic agent

ActiveCN101384623APeptide/protein ingredientsSerum albuminChemical compoundPhenyl group

The present invention provides processes for the production of preformed albumin conjugates. In particular, the invention provides processes for the in-vitro conjugation of a therapeutic compound to recombinant albumin, wherein a therapeutic compound comprising a reactive group is contacted to recombinant albumin in solution to form a conjugate. The processes provide for conjugation to albumin species of increasing homogeneity . The resulting conjugate is purified by chromatography, in particular hydrophobic interaction chromatography comprising phenyl sepharose and butyl sepharose chromatography.

Process for the production of preformed conjugates of albumin and a therapeutic agent

View all

Owner:CHANGSHAN KAIJIEJIAN BIOPHARMACEUTICAL DEV (HEBEI) CO LTD

Methods and Compositions Related to Improving Properties of Pharmacological Agents Targeting Nervous System

InactiveUS20090281031A1Improve blood-brain barrier permeabilityIncreased lipophilic characterNervous disorderPeptide/protein ingredientsNervous systemMedicine

Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.

Methods and Compositions Related to Improving Properties of Pharmacological Agents Targeting Nervous System

View all

Owner:UNIV OF UTAH RES FOUND

Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an Anti-cancer immune response

InactiveUS20190240293A1Relieve symptomsLimited ability to cross blood brain barrierNervous disorderPeptide/protein ingredientsCancer researchNeuroregulator

Described herein are methods for treating a subject having or at risk of developing cancer administering a neuromodulating agent.

Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an Anti-cancer immune response

View all

Owner:FLAGSHIP PIONEERING INNOVATIONS V INC

Peptide yy analogs

InactiveUS20060211610A1Promote weight gainEasy maintenanceBiocidePeptide/protein ingredientsPYY PeptidePYY receptors

The invention provides analogs of PYY. The invention also provides compositions and methods useful for controlling biological activities such as cell proliferation, nutrient transport, lipolysis, and intestinal water and electrolyte secretion.

View all

Owner:IPSEN PHARMA SAS

Methods and compositions for the treatment of neurological disease

InactiveUS20050136036A1Treatment effectRelieve symptomsBiocideNervous disorderNucleic acid sequencingBiology

The present invention relates to a method for delivering a nucleic acid sequence encoding neuropeptide Y, or a derivative or functional fragment thereof, to a mammalian nervous system target cell. The expression of exogenous NPY, or a derivative or a functional fragment thereof in the target cell(s) provides therapeutic benefit for subjects afflicted with a neurological disorder.

Methods and compositions for the treatment of neurological disease

View all

Owner:NEUROLOGIX RESEARCH INC

Stable Analogs of Peptide and Polypeptide Therapeutics

InactiveUS20080051557A1Prolong half-life in vivoLong durationNervous disorderPeptide/protein ingredientsProteolysisChemistry

The present invention relates to compositions of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof.

View all

Owner:BACH BIOSCI LLC

Neuropeptide-2 receptor (Y-2R) agonists and uses thereof

InactiveUS20070135351A1Antibacterial agentsPeptide/protein ingredientsDiseaseDiabetes mellitus

Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.

Neuropeptide-2 receptor (Y-2R) agonists and uses thereof

View all

Owner:F HOFFMANN LA ROCHE & CO AG

Compounds and methods for ¹⁸F labeled agents

ActiveUS8557776B2Good water solubilityImprove bioavailabilityBiocidePeptide/protein ingredientsMedicineChemical compound

The present invention relates to novel compounds suitable for or already radiolabeled with 18F, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characterized by Formula II, wherein the substituents G, Q, L, Y and U have the meaning as defined in the specification and claims.

Compounds and methods for <sup>18</sup>F labeled agents

View all

Owner:BAYER SCHERING PHARMA AG

Neuropeptide-2 receptor (y-2r) agonists

InactiveUS20100069307A1Impaired glucose tolerancePeptide/protein ingredientsMetabolism disorderDense Core VesiclesAgonist

Provided herein are neuropeptide-2 receptor agonists of the formula (I):Y—R1—R2—X—R3—R4—R5—R6—R7—R8—R9—R10—R11—R12—R13—R14—NH2 (I),as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.

View all

Owner:F HOFFMANN LA ROCHE INC

Methods and compositions related to improving properties of pharmacological agents targeting nervous system

InactiveCN101448513APolypeptide with localisation/targeting motifPeptide/protein ingredientsNervous systemMedicine

The present invention discloses compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.

View all

Owner:UNIV OF UTAH RES FOUND

Neuropeptide-2 receptor (Y-2R) agonists and uses thereof

InactiveUS7410949B2Peptide/protein ingredientsMetabolism disorderDiseaseDense Core Vesicles

Provided herein are neuropeptide-2 receptor agonists of the formula (I):Y—R1—R2—X—R3—R4—R5—R6—R7—R8—R9—R10—R11—R12—R13—R14—NH2, (I)as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.

View all

Owner:F HOFFMANN LA ROCHE & CO AG

Neuropeptides and their use for pest control

InactiveUS6884878B2Facilitates passage through the cuticleReduce in quantityBiocideAnimal cellsPest controlDense Core Vesicles

The present invention discloses novel pest control compounds comprising NPF polypeptides and methods for using such compounds in the control of pests.

Neuropeptides and their use for pest control

View all

Owner:UNIV OF FLORIDA RES FOUNDATION INC

Regulation of Specific Spinal Neurons Regulating Pain Transmission

ActiveUS20140255376A1Long-lasting and/or stable and/or reversiblePolypeptide with localisation/targeting motifTachykininsPeptide ligandNeuron

A chimeric toxin is disclosed comprising a peptide ligand specifically targeting neurons involved in pain processing; and a clostridial neurotoxin light chain, wherein the ligand is linked to the light chain. The methods of preparing such chimeric toxin and the method of using the chimeric toxin to regulate pain transmission are also disclosed.

Regulation of Specific Spinal Neurons Regulating Pain Transmission

View all

Owner:RGT UNIV OF CALIFORNIA +1

Methods and compositions for the treatment of neurological disease

InactiveUS7723288B2Alters neuronal excitabilityRelieve symptomsBiocideNervous disorderDiseaseNucleic acid sequencing

View all

Owner:NEUROLOGIX RESEARCH INC

Compounds for control of appetite

ActiveUS20090227519A1Peptide/protein ingredientsMetabolism disorderPancreatic polypeptidomaPancreatic stent

This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and peptide fragments of PP, e.g. PP(32-36), and analogs thereof to pharmaceutical compositions containing such Y4 receptor agonists, and to methods for treatment of mammals using the same. The NPY Y4 receptor agonists may be administered to mammals either alone or in combination with NPY Y2 receptor agonists including peptide (PYY) (3-36), analogs thereof and to peptide fragments of PYY(3-36), e.g. PYY(22-36) and PYY(25-36), and analogs thereof such as to control food intake in mammals, blood pressure, cardiovascular response, libido, circadian rhythm, hyperlipidimia, chronic pancreatitis, and nonalcoholic fatty liver disease including nonalcoholic steatohepatitis.

View all

Owner:UNIVERSITY OF CINCINNATI

Therapeutic peptides

ActiveUS20140329742A1Sugar derivativesPeptide/protein ingredientsDiabetes mellitusObesity

View all

Owner:GLAXOSMITHKLINE INTPROP DEV LTD

Modified Dynorphin Expression in Animals and Identification of Compounds for Treatment of Obesity and Diabetes

InactiveUS20090233840A1Reduce additionalReducing glucose intolerancePeptide/protein ingredientsMetabolism disorderFeeding disorderFat mass

The present invention provides novel transgenic animal models of reduced dynorphin expression in humans that are useful for identifying compounds that are antagonists, inverse agonists, agonists or mimetics of one or more dynorphin peptide products of preprodynorphin. The compounds identified in such screening assays are useful in contexts related to the treatment of obesity and type II diabetes including, for example, improving weight loss and / or reducing appetite during dieting; treating feeding disorders; and for modifying fat mass and reducing glucose intolerance in males.

Modified Dynorphin Expression in Animals and Identification of Compounds for Treatment of Obesity and Diabetes

View all

Owner:GARVAN INST OF MEDICAL RES

Regulation of specific spinal neurons regulating pain transmission via chimeric toxins

ActiveUS9447405B2Long-lasting and/or stable and/or reversiblePeptide/protein ingredientsPharmaceutical delivery mechanismPeptide ligandToxin

View all

Owner:RGT UNIV OF CALIFORNIA +1

Neuropeptide-2 receptor (Y-2R) agonists and uses thereof

InactiveUS20060160742A1Peptide/protein ingredientsMetabolism disorderDiseaseAgonist

Provided herein are neuropeptide-2 receptor agonists of the formula (I): Y—R1—R2—X—R3—R4—R5—R6—R7—R8—R9—R10—R11—R12—R13—R14—NH2 (I), as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.

View all

Owner:F HOFFMANN LA ROCHE & CO AG

Neuropeptide-2 receptor (Y-2R) agonists and uses thereof

InactiveUS7642244B2Antibacterial agentsPeptide/protein ingredientsDiseaseDiabetes mellitus

Provided herein are neuropeptide-2 receptor agonists of the formula (I):as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.

View all

Owner:F HOFFMANN LA ROCHE INC

Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors

ActiveUS20180117170A1Peptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseCyclic peptide

The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.